Lantheus To Acquire Evergreen Theragnostics

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn
The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Lantheus to buy radiopharma CDMO Evergreen Theragnostics for $250M upfront
Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront.
Lantheus’s Strategic Acquisition of Evergreen Theragnostics Strengthens Radiopharmaceutical Leadership and Growth Prospects
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Invest with Confidence:
Lantheus Holdings to Acquire Evergreen Theragnostics
Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Lantheus to acquire Evergreen Theragnostics for $250M upfront
Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of
Lantheus Shares Down Nearly 9% On News Of Evergreen Theragnostics Acquisition
Lantheus Holdings, Inc. (LNTH), a radiopharmaceutical company, experienced a 9% drop in its stock price on Tuesday after announcing a
Hosted on MSN1d
LNTH: Evergreen Acquisition Promotes Future Innovation
LNTH Lantheus to Buy Evergreen Theragnostics Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this ...
Outsourcing-pharma1d
Lantheus to acquire Evergreen in $1bn deal to expand radiopharmaceutical pipeline
Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...
Lantheus is on a buying spree. Its latest deal is worth up to $1B
Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...
FiercePharma3d
Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen
On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...
Why Lantheus Holdings Stock Got Thrashed on Tuesday
Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage ...